EBEka Budiarto

Eka Budiarto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eka Budiarto has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Hybrid COBIT 2019–RAG Framework to Enhance Consumer Protection Compliance in Digital Finance

    by Edy Salim, Mohammad Achmad Amin Soetomo, Eka Budiarto

    The rapid growth of digital financial services has increased the need for effective regulatory compliance mechanisms, particularly for consumer protection. This study develops and evaluates a hybrid COBIT 2019–Retrieval-Augmented Generation (RAG) framework for compliance with Indonesia’s OJK Regulation No. 22/2023 in a digital multifinance context. Using a design science research methodology, COBIT 2019 design factors were applied to tailor governance objectives, while a RAG pipeline was evaluated on 100 synthetic compliance queries using RAGAS metrics and expert-validated reference answers. The governance assessment prioritized EDM03, APO12, and MEA03, each assessed at capability Level 2 against a target of Level 4, indicating gaps in risk optimization, risk management, and external compliance. The optimal RAG configuration achieved an overall score of 0.8257, with context recall of 0.9217, faithfulness of 0.8502, and semantic similarity of 0.8629. It also outperformed baseline keyword search in retrieving semantically relevant regulatory passages, although broader benchmarking remains limited. The findings show that integrating structured IT governance with AI-assisted regulatory retrieval can strengthen accountability, regulatory interpretation, and compliance decision support. The framework offers a scalable approach for regulated industries, subject to further validation using real operational data and broader institutional settings.

  • Open Access

    Investigation of alpha-glucosidase inhibition activity of Artabotrys sumatranus leaf extract using metabolomics, machine learning and molecular docking analysis

    by Dela Rosa, Berna Elya, Muhammad Hanafi, Alfi Khatib, Eka Budiarto, Syamsu Nur, Muhammad Imam Surya

    One way to treat diabetes mellitus type II is by using α-glucosidase inhibitor, that will slow down the postprandial glucose intake. Metabolomics analysis of Artabotrys sumatranus leaf extract was used in this research to predict the active compounds as α-glucosidase inhibitors from this extract. Both multivariate statistical analysis and machine learning approaches were used to improve the confidence of the predictions. After performance comparisons with other machine learning methods, random forest was chosen to make predictive model for the activity of the extract samples. Feature importance analysis (using random feature permutation and Shapley score calculation) was used to identify the predicted active compound as the important features that influenced the activity prediction of the extract samples. The combined analysis of multivariate statistical analysis and machine learning predicted 9 active compounds, where 6 of them were identified as mangiferin, neomangiferin, norisocorydine, apigenin-7-O-galactopyranoside, lirioferine, and 15,16-dihydrotanshinone I. The activities of norisocorydine, apigenin-7-O-galactopyranoside, and lirioferine as α-glucosidase inhibitors have not yet reported before. Molecular docking simulation, both to 3A4A (α-glucosidase enzyme from Saccharomyces cerevisiae, usually used in bioassay test) and 3TOP (a part of α-glucosidase enzyme in human gut) showed strong to very strong binding of the identified predicted active compounds to both receptors, with exception of neomangiferin which only showed strong binding to 3TOP receptor. Isolation based on bioassay guided fractionation further verified the metabolomics prediction by succeeding to isolate mangiferin from the extract, which showed strong α-glucosidase activity when subjected to bioassay test. The correlation analysis also showed a possibility of 3 groups in the predicted active compounds, which might be related to the biosynthesis pathway (need further research for verification). Another result from correlation analysis was that in general the α-glucosidase inhibition activity in the extract had strong correlation to antioxidant activity, which was also reflected in the predicted active compounds. Only one predicted compound had very low positive correlation to antioxidant activity.


  • Open Access

    Prediction model for composite adverse pregnancy outcomes: Indonesia demographic health survey analysis

    by Eka Santy Abdurrahman, Eka Budiarto, Indrajani Sutedja, Narila Mutia Nasir, Besral, Indonesia Universitas Indonesia, Alias Masek, Kemal Nazaruddin Siregar

    Adverse Pregnancy Outcome (APO) is the leading cause of infant mortality, particularly in low and middle-income countries. Despite no significant change in neonatal mortality rates in Indonesia over the past fifteen years, identifying the risk factors for APO can help healthcare professionals provide personalized interventions and support. This study aims to determine the determinants of APO risk in Indonesia. The cross-sectional study utilized the 2017 Indonesian Health Demographic Survey (IDHS), which included 9,752 women of reproductive age. APO, including low birth weight, early birth, and stillbirth, was the outcome of the study. The demographic characteristics and other risk factors were evaluated. To identify APO-risk-associated factors, we performed multiple logistic regression analysis. The results showed that low economic status (Adj. OR= 1.407; 1.153-1.716; p= 0.001)), living in rural areas (Adj. OR= 0.804; 0.663-0.976; p= 0.027), having a history of pregnancy or childbirth complications (Adj. OR= 4.563; 3.617-5.756; p= 0.0001), premature rupture of the membrane during pregnancy or after giving birth (Adj. OR= 1.351; 1.069-1.708; p= 0.012), antenatal visits <4 times (Adj. OR= 1.603; 1.123-2.288; p= 0.009), consumption of iron supplement tablets <90 days (Adj. OR= 1.275; 1.063-1.529; p= 0.009), and twin pregnancy (Adj. OR= 33.715; 18.587-61.153; p= 0.0001) significantly influenced the APO prevalence. The study concluded that APO risk is significantly impacted by poor obstetric history features, multiple births, low health service utilization, and sociodemographic factors. Early detection of these risk factors is essential for reducing neonatal death caused by APO.